avatrombopag
Phase 1Completed 0 watching 0 views this weekπ€ Quiet
33
Development Stage
β
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Thrombocytopenia
Conditions
Thrombocytopenia
Trial Timeline
Dec 1, 2013 β Sep 1, 2014
NCT ID
NCT02039076About avatrombopag
avatrombopag is a phase 1 stage product being developed by Eisai for Thrombocytopenia. The current trial status is completed. This product is registered under clinical trial identifier NCT02039076. Target conditions include Thrombocytopenia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02039076 | Phase 1 | Completed |
Competing Products
20 competing products in Thrombocytopenia